Latest Expert Opinions

Signal
Opinion
Expert
TOP PICK
TOP PICK
December 3, 2018
A long-time top pick. Their entire business line works, particularly immunotherapies. It's had a great run. He writes covered calls on this to generate extra income. (Analysts’ price target is $81.25)
Merck & Company(MRK-N)
December 3, 2018
A long-time top pick. Their entire business line works, particularly immunotherapies. It's had a great run. He writes covered calls on this to generate extra income. (Analysts’ price target is $81.25)
Paul Macdonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$79.220
Owned
Yes
TOP PICK
TOP PICK
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Celgene Corp(CELG-Q)
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Paul Macdonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$73.420
Owned
Yes
TOP PICK
TOP PICK
December 3, 2018
They've had a great run and are the poster child of the U.S. health insurance space. They continue to put up 15% bottom-line growth. (Analysts’ price target is $304.74)
They've had a great run and are the poster child of the U.S. health insurance space. They continue to put up 15% bottom-line growth. (Analysts’ price target is $304.74)
Paul Macdonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$286.330
Owned
Yes